Project Details
Description
Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
| Status | Active |
|---|---|
| Effective start/end date | 2/1/24 → 2/28/34 |
Funding
- JOHNS HOPKINS UNIVERSITY
- MIRATI THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.